Quad Marker Screening - One blood specimen drawn at 15 weeks - 20 weeks of pregnancy (second trimester test).
Serum Integrated Screening - Combines a first trimester blood test screening result (10 weeks-13 weeks 6 days) with a second trimester blood test screening result (15 weeks-20 weeks).
Sequential Integrated Screening - Combines first and second blood test results with Nuchal Translucency (NT) ultrasound results. This type of ultrasound is done by clinicians with special training. It measures the back of the fetus' neck. This measurement helps screen for Down syndrome (trisomy 21). (Note: the Screening Program does not pay for NT ultrasounds).
The Prenatal Screening Program provides pregnant women with a risk assessment for open neural tube defects (NTD), Down syndrome (trisomy 21), trisomy 18 and SLOS (Smith-Lemli-Opitz Syndrome) through one or two blood tests. The screening test indicates risk, but does not diagnose fetal birth defects.
For women with screening results indicating a high risk for a birth defect, the Program provides free follow-up diagnostic services at State-approved Prenatal Diagnosis Centers (PDCs) (PDF). Services offered at these Centers include genetic counseling, ultrasound, and amniocentesis. Participation in the screening testing and follow-up services is voluntary. The cost of the testing through the Prenatal Screening Program is $221.60.